Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
Kavakli, K. 1; Yang, R. 2; Rusen, L. 3; Beckmann, H. 4; Tseneklidou-Stoeter, D. 5; Enriquez, Maas M. 4; Yang, Renchi; Zhao, Yongqiang; Sun, Jing; Wang, Xuefeng; Wu, Depei; Hlusi, Antonin; Fukutake, Katsuyuki; Hanabusa, Hideji; Fujii, Teruhisa; Ramirez, Oscar Perez; Alvarado, Blanca Salazar; Serban, Margit; Rusen, Luminita; Uscatescu, Valentina; Truica, Cristina; Kostic, Gordana; Konstantinidis, Nada; Igrutinovic, Zoran; Perina, Farida; Andreeva, Tatiana; Kavakli, Kaan; Antmen, Bulent; Sasmaz, Ilgen; Kupesiz, Alphan; Yesilipek, Mehmet Akif; Peng, Ching-Tien; French, James II; Escobar, Miguel; Mahlangu, Johnny; Pool, Roger
[Article] Journal of Thrombosis & Haemostasis. 13(3):360-369, March 2015.

(Format: HTML, PDF)